PDS Biotechnology CorpPDSB
Price$0.71

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$33.7MTTM through 30 Jun 2026
Free Cash Flow -$16.8MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%

Returns

-346.0%ROE
-102.4%ROA

Balance Sheet Health

Debt / Equity2.72x
Current Ratio0.57x
Net Debt-$11.1Mnet cash position
Cash & Equivalents$5.6M

Quality Metrics

Altman Z-Score-45.11
Piotroski F-Score1 / 9
Earnings-Beat Rate100.0%

Multi-Year Trend

Diluted EPS-$0.64TTM
'20'21'22'23'24'25
FY2025: $-0.74

Dividend

No dividend

Capital Allocation

R&D Spend$15.7M

Segment Performance

SegmentRevenueYoYOutlook
Immunotherapy Pipeline$00.0%
View details

The company continues to focus resources on its lead clinical candidates, PDS0101 and PDS01ADC, utilizing its proprietary Versamune and Infectimune platforms.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.